Cargando…

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation, marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic stem cell transplant is the only potentially curative therapy for this disease, however, survival gains observed for oth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perram, Jacinta, Ross, David M., McLornan, Donal, Gowin, Krisstina, Kröger, Nicolas, Gupta, Vikas, Lewis, Clinton, Gagelmann, Nico, Hamad, Nada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Critical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796730/ https://www.ncbi.nlm.nih.gov/pubmed/35802782 http://dx.doi.org/10.1002/ajh.26654

Ejemplares similares

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Not all mismatches are equal: importance of alloreactivity direction
por: Perram, Jacinta, et al.
Publicado: (2021)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?
por: Gagelmann, Nico, et al.
Publicado: (2021)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
por: Mesa, Ruben, et al.
Publicado: (2022)

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
por: Mesa, Ruben A., et al.
Publicado: (2023)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
por: Win, Hninyee, et al.
Publicado: (2020)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
por: Mesa, Ruben A., et al.
Publicado: (2023)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic
por: Worthington, Atesh K., et al.
Publicado: (2022)

Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy
por: Mann, Shivtaj, et al.
Publicado: (2020)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma
por: Perram, Jacinta, et al.
Publicado: (2014)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models
por: Pandya, Shaunak K., et al.
Publicado: (2023)

Intravesical recurrence of chromophobe renal cell carcinoma
por: Kelly, Niall P., et al.
Publicado: (2023)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research
por: Eckert, Ryan, et al.
Publicado: (2016)

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
por: Khan, Alesia, et al.
Publicado: (2021)

Urosepsis and the urologist!
por: Ryan, James, et al.
Publicado: (2021)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9c5435vgomiqn3hfdc61ursr6u